The Role of Epac2 as a new target of sulfonylurea drugs
| Project/Area Number |
22790860
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
TAKAHASHI Harumi 神戸大学, 大学院・医学研究科, 学術推進研究員 (50546489)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 糖尿病 / インクレチン / スルホニル尿素薬 / インスリン分泌 / 膵β細胞 / cAMP / Epac2 |
|---|
| Research Abstract |
Incretin/cAMP signaling and sulfonylurea synergistically augment insulin secretion from pancreatic β-cell. This interacting effect involves the enhancement of Epac2/Rap1 signaling and depends on the action of sulfonylureas on Epac2.
|
Report
(4 results)
Research Products
(44 results)
